BRIEF—Chinese endorsement for eXithera's anti-coagulant

Sichuan Haisco Pharmaceutical likes the look of privately-held US biotech eXithera Pharmaceuticals, reports Globes.

The Chinese company has paid for rights to develop, manufacture, and market eXithera’s intravenous EP-7041 anti-coagulant, which is in clinical development for complex cardiac surgery, in China.

eXithera is one of the portfolio companies of Israeli life sciences investment company Clal Biotechnology Industries (TLV: CBI). Its focus is on developing new, potent and selective small molecule Factor XIa inhibitors designed to prevent thrombosis with limited risk for bleeding side effects and without the need for a reversal agent.

Haisco’s investment will see Clal’s stage in eXithera reduce to 45%.